Anumana, InfoBionic.Ai Team Up for AI-Powered, Remote Cardiac Telemetry

Anumana and InfoBionic.Ai revealed a joint research collaboration to develop and commercialize the next generation of remote cardiac care solutions.
 
The deal will combine Anumana’s ECG-AI technology and InfoBionic.Ai’s MoMe ARC platform. Merging the two aims to boost MoMe ARC’s ability to spot and intervene in cardiac diseases earlier in the remote patient monitoring setting. Both companies are part of the Mayo Clinic portfolio and said they will keep working closely with Mayo Clinic under the research agreement.
 
Anumana has earned U.S. Food and Drug Administration (FDA) breakthrough status for its low ejection fraction (LEF), pulmonary hypertension, cardiac amyloidosis, and hyperkalemia algorithms. ECG-AI LEF uses routine 12-lead ECG data to spot LEF, which is a frequently undiagnosed indicator for heart failure. It was cleared by the FDA in October 2023.
 
The company has also shown its ECG-AI tech can be adapted to lower-lead ECG devices while keeping a high degree of performance.
 
InfoBionic.Ai’s MoMe ARC is a continuous, six-lead, FDA cleared platform that uses AI analysis and native business intelligence. It includes a four-in-one Gateway device to transition between two-day and extended Holter tests, event, and MCT modes remotely.
 
The duo will develop and integrate Anumana’s ECG-AI algorithms, beginning with the FDA-cleared ECG-AI LEF algorithm, into InfoBionic.Ai’s continuous, remote cardiac monitoring platform. This aims to detect LEF and other conditions via remote cardiac activity monitoring. The two companies will also collaborate to validate the integrated solution’s clinical utility and pursue regulatory clearance.
 
“It is exciting to see the convergence of our pioneering work in artificial intelligence and remote patient monitoring through this new partnership between Anumana and InfoBionic.Ai,” said Peter Noseworthy, MD, chair of the Heart Rhythm Services Division of Cardiovascular Medicine at Mayo and a board director at InfoBionic.Ai. “By combining InfoBionic.Ai’s remote monitoring solutions with Anumana’s innovative ECG-AI algorithms, including the FDA-cleared algorithm for detecting low ejection fraction (LEF), we aim to equip healthcare providers with the latest cutting-edge tools to detect underlying cardiac conditions earlier, enabling timely intervention and personalized care. It’s a thrilling time for cardiology.”
 
Anumana also received ISO 13485 certification for its quality management system last week.
 
“This collaboration marks an important step in Anumana’s mission to revolutionize cardiac care by enhancing the power of ECG with AI,” added Maulik Nanavaty, CEO of Anumana. “Since the founding of Anumana, our vision has been to elevate the utility of ECG with AI across all the settings in which ECGs are used. By joining forces with InfoBionic.Ai, we are expanding our capabilities from 12 leads in clinical settings to wearable lower-lead ECGs in patients’ homes. We look forward to bringing our AI technology to meet patients and physicians where they are, ultimately benefiting both worldwide.”